Richard A Morgan, Peter J Weng, Sandra S Stinnett, Dilraj S Grewal, Sharon Fekrat
{"title":"多巴胺能治疗可降低早期和中期非渗出性年龄相关性黄斑变性进展的风险。","authors":"Richard A Morgan, Peter J Weng, Sandra S Stinnett, Dilraj S Grewal, Sharon Fekrat","doi":"10.3928/23258160-20250326-02","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Age-related macular degeneration (AMD) is a leading cause of vision loss, with progression to geographic atrophy (GA) posing a significant challenge. This study aimed to assess whether dopaminergic therapies (DMTs) reduce risk of AMD progressing to GA.</p><p><strong>Patients and methods: </strong>A retrospective cohort study analyzed electronic health records of 320 patients (449 eyes) with early or intermediate nonexudative AMD at Duke Eye Center from 2014 to 2024. Of these, 80 patients (110 eyes) were on DMTs, and 240 (339 eyes) served as controls. GA progression was evaluated annually over 5 years.</p><p><strong>Results: </strong>GA progression was lower in the DMT group across all intervals, with lifetime rates of 9.4% in the non-DMT group versus 2.7% in the DMT group (<i>P</i> < 0.05). Multivariate analysis showed a significant protective effect (odds ratio 0.08, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>DMTs may significantly reduce risk of AMD progressing to GA, warranting further research. <b>[<i>Ophthalmic Surg Lasers Imaging Retina</i> 2025;56:XX-XX.]</b>.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-6"},"PeriodicalIF":0.9000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dopaminergic Therapies May Decrease Risk of Early and Intermediate Non-exudative Age-related Macular Degeneration Progression.\",\"authors\":\"Richard A Morgan, Peter J Weng, Sandra S Stinnett, Dilraj S Grewal, Sharon Fekrat\",\"doi\":\"10.3928/23258160-20250326-02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Age-related macular degeneration (AMD) is a leading cause of vision loss, with progression to geographic atrophy (GA) posing a significant challenge. This study aimed to assess whether dopaminergic therapies (DMTs) reduce risk of AMD progressing to GA.</p><p><strong>Patients and methods: </strong>A retrospective cohort study analyzed electronic health records of 320 patients (449 eyes) with early or intermediate nonexudative AMD at Duke Eye Center from 2014 to 2024. Of these, 80 patients (110 eyes) were on DMTs, and 240 (339 eyes) served as controls. GA progression was evaluated annually over 5 years.</p><p><strong>Results: </strong>GA progression was lower in the DMT group across all intervals, with lifetime rates of 9.4% in the non-DMT group versus 2.7% in the DMT group (<i>P</i> < 0.05). Multivariate analysis showed a significant protective effect (odds ratio 0.08, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>DMTs may significantly reduce risk of AMD progressing to GA, warranting further research. <b>[<i>Ophthalmic Surg Lasers Imaging Retina</i> 2025;56:XX-XX.]</b>.</p>\",\"PeriodicalId\":19679,\"journal\":{\"name\":\"Ophthalmic surgery, lasers & imaging retina\",\"volume\":\" \",\"pages\":\"1-6\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic surgery, lasers & imaging retina\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3928/23258160-20250326-02\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20250326-02","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Dopaminergic Therapies May Decrease Risk of Early and Intermediate Non-exudative Age-related Macular Degeneration Progression.
Background and objective: Age-related macular degeneration (AMD) is a leading cause of vision loss, with progression to geographic atrophy (GA) posing a significant challenge. This study aimed to assess whether dopaminergic therapies (DMTs) reduce risk of AMD progressing to GA.
Patients and methods: A retrospective cohort study analyzed electronic health records of 320 patients (449 eyes) with early or intermediate nonexudative AMD at Duke Eye Center from 2014 to 2024. Of these, 80 patients (110 eyes) were on DMTs, and 240 (339 eyes) served as controls. GA progression was evaluated annually over 5 years.
Results: GA progression was lower in the DMT group across all intervals, with lifetime rates of 9.4% in the non-DMT group versus 2.7% in the DMT group (P < 0.05). Multivariate analysis showed a significant protective effect (odds ratio 0.08, P < 0.001).
Conclusion: DMTs may significantly reduce risk of AMD progressing to GA, warranting further research. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].
期刊介绍：
OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
